Clinical adenoviral gene therapy for prostate cancer.
Human Gene Therapy , Volume 21 - Issue 7 p. 807- 813
Prostate cancer is at present the most common malignancy in men in the Western world. When localized to the prostate, this disease can be treated by curative therapy such as surgery and radiotherapy. However, a substantial number of patients experience a recurrence, resulting in spreading of tumor cells to other parts of the body. In this advanced stage of the disease only palliative treatment is available. Therefore, there is a clear clinical need for new treatment modalities that can, on the one hand, enhance the cure rate of primary therapy for localized prostate cancer and, on the other hand, improve the treatment of metastasized disease. Gene therapy is now being explored in the clinic as a treatment option for the various stages of prostate cancer. Current clinical experiences are based predominantly on trials with adenoviral vectors. As the first of a trilogy of reviews on the state of the art and future prospects of gene therapy in prostate cancer, this review focuses on the clinical experiences and progress of adenovirus-mediated gene therapy for this disease.
|Human Gene Therapy|
|Organisation||Department of Urology|
Schenk-Braat, E.A.M, Essand, M, Bangma, C.H, GIANT FP6 Consortium, ., Barber, C, Behr, J.P, … Willemsen, R.A. (2010). Clinical adenoviral gene therapy for prostate cancer.. Human Gene Therapy (Vol. 21, pp. 807–813). Retrieved from http://hdl.handle.net/1765/90808